Role Of Real-time PCR Detection Of Her-2 Amplification In Study Of The Mechanisms Of Neoadjuvant Chemotherapy For Breast Cancer

Background: Breast cancer is a serious threat to today's world women's health. In our country its incidence shows increasing trend. As people know more about its characteristics, they don't treat breast cancer only by surgery any longer, but pay great attention to neoadjuvant chemotherapy, which means the patients receive chemotherapy before undergo an operation. To operable breast cancer patients, it has the advantage of elimination the micro-transfer lesions in other parts of body, avoiding rapid growth of metastasis focus after the primary tumor resected., and may prevent development of tumor cell's drug-resistant. But people still know little about the difference between the change of tumor cells caused by neoadjuvant chemotherapy and post-operation chemotherapy on cell and molecular level (it may lead to different outcomes). So they begin to carry out a series of basic and clinic research on some new biological factors with new methods to understand this new therapy on molecular level, which is aimed to increase the overall effect.Her-2 gene is closely related to the occurrence and development of breast cancer confirmed by research. It can promote excessive growth of cells by acting on some signal transduction pathways. Patients with Her-2 gene amplified are always prone to recurrence and metastasis after operation, as their high proliferation activity tumor cells. There have been many studies on the mutual relations between Her-2 gene and neo-adjuvant chemotherapy done by domestic and foreign scholars, but they do not reach a unanimous conclusion presently.Aim: To detect Her-2 gene's volume both before and after neoadjuvant chemotherapy in the same group of breast cancer patients and investigate the variety regularity. And discus how chemotherapy drugs modulate on the expression of prognostic factors preliminarily.Method: The Her-2 gene's volume in 28 cases of pre and post neoadjuvant chemotherapy breast cancer was detected by real-time PCR. We investigated the difference of Her-2 gene's volume between pre and post neoadjuvant chemotherapy.Result: The results of real-time PCR showed that for the same group of breast cancer patients, the volume of Her-2 gene in 28 cases of pre neoadjuvant chemotherapy breast cancer was significantly higher than those treated by neoadjuvant chemotherapy . But so far we haven't seen the association between the alteration extent of Her-2 gene's volume and the patients' clinic staging or the number of neoadjuvant chemotherapy cycles.Conclusion: Neoadjuvant chemotherapy can make Her-2 gene's volume reduced in breast cancer. Real-time PCR is a good way to detect breast cancer Her-2 gene's expression.